US 9066980

I'll search for the specific patent number and check current litigation status.

US Patent 9,066,980 — Verification Summary

I searched for the literal number 9066980 (never auto-corrected) against Google Patents, DrugPatentWatch, Justia/court records, and general Federal Circuit coverage. Below is what I can confirm; I flag uncertainties explicitly.

⚠️ Important framing note on the "CAFC 2026 dockets" request: I found no 2026 Federal Circuit docket activity involving U.S. Patent 9,066,980 in searches of CAFC opinion summaries, Federal Circuit watch digests, and litigation databases. The only Federal Circuit litigation history tied to this patent family is the Helsinn v. Teva appeals (Fed. Cir. 2017; U.S. Supreme Court 2019), none of which involved the '980 patent as an asserted claim set on appeal. I cannot confirm any CAFC 2026 docket for this patent exists — treat "none found" rather than "none exists" as my conclusion, since I do not have direct docket-level access.

Bibliographic Data (verified)

Discrepancy I must flag (not auto-corrected): Google Patents lists the grant date as 2015-06-30, but the D.N.J. infringement opinion states the '980 patent "issued on June 20, 2015." I am reporting both literally without harmonizing them. My best assessment is that the two sources disagree on the day of issue (30 vs. 20); I do not have authoritative confirmation of which is correct.

Family/continuity (verified): The '980 patent is a continuation of US 13/901,437 (issued as US 8,598,219), and traces through 13/087,012 (US 8,518,981), 11/186,311 (US 7,947,724), PCT/EP2004/000888 (WO 2004/067005 A1), and provisional 60/444,351. A child continuation, US 14/597,489, issued as US 9,125,905.

Abstract (verbatim)

"The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments."

Plain-Language Overview of the Independent Claims

Claim 1 — the core formulation claim
A ready-to-use, single-use, unit-dose product for IV injection into a human, to lower the chance of chemotherapy-induced nausea and vomiting (CINV). It is defined as a 5 mL sterile aqueous solution containing three things:

• (a) palonosetron hydrochloride, 0.25 mg (measured as the free base — i.e., the marketed Aloxi 0.25 mg/5 mL dose);
• (b) optionally a chelating agent (the word "optionally" means a chelating agent is not required to infringe this claim — this became the key issue in litigation);
• (c) a tonicifying agent in an amount sufficient to make the solution isotonic;
• plus the functional limitation that the formulation is stable for 24 months at room temperature.

Claim 12 — the method-of-treatment claim
A method of reducing the likelihood of CINV by intravenously administering the Claim 1 formulation to a human, where the administration occurs before chemotherapy starts (i.e., prophylactic pre-treatment dosing).

Claim 16 — the second formulation claim
Identical in scope to Claim 1 in every respect except the stability term: it requires stability at 18 months at room temperature (rather than 24 months). It is effectively a fallback/belt-and-suspenders independent claim covering a slightly shorter shelf-life guarantee.

Dependent claims narrow these: pH buffered at 5.0 ± 0.5 (c.2); mannitol as the tonicifying agent, 10–80 mg/mL, optimally 41.5 mg/mL (c.3–5); a chelating agent, preferably EDTA at 0.005–1.0 mg/mL, optimally 0.5 mg/mL (c.6–9); a citrate buffer, optimally 20 mM (c.10–11); and administration over 10–60 seconds, reducing acute or delayed nausea/vomiting (c.13–15).

Litigation Context (verified, relevant to this exact patent)

• Helsinn Healthcare S.A. v. Dr. Reddy's Labs., Ltd., No. 12-2867 (D.N.J.) — the '980 patent was asserted alongside the '724 and '094 patents. The court's Feb. 14, 2017 opinion found the asserted claims (including '980 claims 1, 2, 3, 4, 5, and 16, with claim 6 as the non-infringement claim) infringed and not invalid for lack of enablement or written description, turning on whether acetate counted as a "chelating agent." URL: https://www.jdsupra.com/post/contentViewerEmbed.aspx?fid=892df706-1b68-4bf2-8236-8dbaaefd26b6
• Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, No. 1:15-cv-00918 (D. Del., filed Oct. 13, 2015; terminated Dec. 2, 2015) — patents listed included 9,066,980. URL: https://www.drugpatentwatch.com/p/litigation/casename/index.php?query=Helsinn+Healthcare+S.A.+v.+Fresenius+Kabi+USA%2c+LLC%7c1%3a15-cv-00918
• Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc. — the Federal Circuit (855 F.3d 1356, May 1, 2017) invalidated four different palonosetron formulation patents ('724, '725, '424, '218) under the AIA on-sale bar; the U.S. Supreme Court affirmed in 2019. The '980 patent was not among the patents invalidated on that appeal.

Confidence / Uncertainty Statement

• High confidence: title, application number, filing date, priority chain, inventors, assignees (original and current), claim text, abstract, 16-claim count, and expired status — all corroborated across Google Patents, DrugPatentWatch, and federal court opinions I retrieved.
• Explicit uncertainty: the issue date (June 20 vs. June 30, 2015 — sources conflict), and the absence of any 2026 CAFC docket (I found none, but cannot affirmatively rule it out without direct PACER/CAFC docket access). If you need docket-level certainty, verify against the CAFC's public docket and PACER directly rather than relying on my search results.

I'll research litigation involving US patent 9066980. Let me search multiple sources.

Let me get the full Stanford NPE database page and search for specific cases.

Let me search for more specific case details and the complete list.

I've reached my tool-use limit. Here is what I was able to verify about litigation involving US 9,066,980 B2 ("Liquid pharmaceutical formulations of palonosetron," palonosetron/aloxi). Note that I was unable to retrieve the complete case list from the Stanford NPE database or PACER before hitting my search limit, so the list below is what I could confirm from the sources returned.

Important framing: Several of the cases below involve multi-patent ANDA (Hatch‑Waxman) suits in which the '980 patent was one of several patents‑in‑suit, not the sole patent. I flag below which cases explicitly identify U.S. 9,066,980 as a patent‑in‑suit.

Confirmed cases naming U.S. 9,066,980

1. Helsinn Healthcare S.A. et al. v. Fresenius Kabi USA, LLC

• Plaintiffs: Helsinn Healthcare S.A. and Roche Palo Alto LLC
• Defendant: Fresenius Kabi USA, LLC
• Jurisdiction: U.S. District Court for the District of Delaware
• Case No.: 1:15‑cv‑00918 (Judge Gregory Moneta Sleet)
• Filed: 2015‑10‑13
• Patents‑in‑suit: 7,947,724; 8,518,981; 8,598,218; 9,066,980; 9,125,905 (cause 35:0145, ANDA)
• Outcome/status: Terminated 2015‑12‑02 by notice of voluntary dismissal without prejudice as to all claims (docket item 7, filed 2015‑12‑01). (Source: D. Del. docket via CourtListener / DrugPatentWatch)

2. Helsinn Healthcare S.A. et al. v. Fresenius Kabi USA, LLC et al.

• Plaintiffs: Helsinn Healthcare S.A. and Roche Palo Alto LLC
• Defendants: Fresenius Kabi USA, LLC; Hospira, Inc.; Hospira Worldwide, Inc. (and others)
• Jurisdiction: U.S. District Court for the District of New Jersey
• Case No.: 3:15‑cv‑07378
• Patents‑in‑suit: 7,947,724; 7,947,725; 7,960,424; 8,598,219; 8,729,094; 8,518,981; 8,598,218; 9,066,980
• Outcome/status: This action was consolidated/related to the palonosetron MDL-style proceedings in D.N.J.; I could not confirm a final disposition from the sources retrieved. (Source: Docket Alarm document 55 in 3:15‑cv‑07378)

3. Helsinn Healthcare S.A. et al. v. Actavis LLC

• Plaintiffs: Helsinn Healthcare S.A. and Roche Palo Alto LLC
• Defendant: Actavis LLC
• Jurisdiction: U.S. District Court for the District of New Jersey (Judge Stanley R. Chesler; Magistrate Cathy L. Waldor)
• Case No.: 2:16‑cv‑01683
• Filed: 2016‑03‑24
• Patents‑in‑suit: 7,947,724 and 9,066,980 (cause 35:271)
• Outcome/status: Terminated 2019‑05‑15. The action was stayed pending resolution of Civil Action No. 14‑4274; it ended by stipulated dismissal without prejudice after Actavis requested withdrawal of its NDA No. 208426 (approximately Feb. 22, 2019), which mooted the claims. (Source: CourtListener dockets 6127739, entries 103–106)

4. Helsinn Healthcare S.A. v. [Dr. Reddy's Laboratories, Ltd.](/litigations/by-defendant/Dr.%20Reddy's%20Laboratories%2C%20Ltd.) et al.

• Plaintiff: Helsinn Healthcare S.A.
• Defendants: Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc.
• Jurisdiction: U.S. District Court for the District of New Jersey (Judge Claire C. Cecchi / Judge Cooper)
• Case Nos.: C.A. No. 12‑2867 (consolidated) and C.A. No. 14‑4274 (separate suit asserting the '094 and '980 patents)
• Patents‑in‑suit (for the '980 portion): U.S. 9,066,980; U.S. 8,729,094; and 7,947,724
• Outcome/status: On February 14, 2017, the court found the asserted claims of the '980 patent infringed and not invalid (DRL's § 112 written‑description and enablement defenses rejected). Specifically, claims 1–5 and 16 were stipulated infringed; claim 6 was tried and also found infringed. (Helsinn Healthcare S.A. v. Dr. Reddy's Labs., Ltd., No. 12‑2867, 2017 U.S. Dist. LEXIS 21477 (D.N.J. Feb. 14, 2017); Robins Kaplan / Life Sciences IP Review summaries)

Related/adjacent proceedings (NOT direct '980 suits — flagging to avoid confusion)

• Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc. (Fed. Cir., 855 F.3d 1356, 2017; and U.S. Supreme Court, 139 S. Ct. 628 (2019)) — this on‑sale‑bar case concerned the related '219, '724, '725 and '424 patents, not the '980 patent. It is frequently cited in proximity to the '980 litigation but should not be attributed to '980.
• Google Patents lists several additional district‑court dockets referencing the patent family (e.g., D. Del. 1:15‑cv‑00918; D.N.J. 3:15‑cv‑07378; D.N.J. 2:16‑cv‑01683; E.D. Pa. 2:15‑cv‑06392; D.N.J. 1:16‑cv‑01394; D.N.J. 3:16‑cv‑01683). I was not able to confirm from the retrieved sources that all of these specifically assert U.S. 9,066,980 as opposed to other family members.

Caveats / confidence

• The existence of cases 1, 2, 3 and 4 as listing U.S. 9,066,980 is well supported by the sources returned (CourtListener, DrugPatentWatch, Docket Alarm, and the D.N.J. Feb. 14, 2017 opinion).
• I could not fully retrieve the Stanford NPE Litigation Database table (the page at https://npe.law.stanford.edu/patent/9066980 listed at least 4 cases but truncated cases #2 and #4), so there may be additional defendants/cases (e.g., other generic ANDA filers such as Sandoz, Cipla, Aurobindo, Mylan, Exela, Gavis, etc.) that also named the '980 patent and that I did not capture.
• Filing dates, dispositions and judge assignments are drawn from the secondary dockets shown and should be confirmed against PACER for a definitive, current record before being relied on for any legal purpose.

If you want, I can (in a follow‑up, given more tool budget) pull the full Stanford NPE case list and the complete PACER docket sheets for each case to fill the gaps above.

I'll verify the structured data against public sources before drafting.

Search results surfaced a palonosetron IPR exhibit reference (IPR2016-00007). Let me pin down which patents those petitions targeted.

Let me check the Palonosetron patent PTAB docket list and any petitions specifically targeting the '980 patent.

I'll attempt to pull the actual USPTO assignment records (reel/frame, correspondent) before writing, since those fields aren't present in the source text I was given.

Let me try to pin down the security-interest holder and Roche entity status, plus any assignment reel/frame data.

Sourcing caveat (read first): I could reach the web-search index but not the live USPTO Assignment Center query interface. The authoritative Google Patents legal‑events block I was given lists the existence, date, conveyance type, assignors, and assignees of each post‑issuance transfer, but it does not expose reel/frame numbers or the correspondent of record. My searches (Google Patents, Stanford NPE Litigation Database, FDA ANDA letters, CourtListener, PTAB/CAFC papers) also failed to surface reel/frame or correspondent data for US 9,066,980. I am therefore reporting reel/frame and correspondent as "not retrievable," not as absent. Do not treat the blanks below as "no record." Verify at https://assignmentcenter.uspto.gov/ (search by patent number 9066980) before relying on any field.

Inventors

Unusual patterns worth flagging (evidence‑based, not inference):

• Inventor set is inconsistent within the same family. The related parent U.S. 8,518,981 front page lists six inventors (Calderari, Bonadeo, Cannella, Miksztal, Malefyt, Lee — tied to assignees "Helsinn Healthcare SA, Lugano/Pazzallo (CH); Roche Palo Alto LLC, Palo Alto, CA (US)"), while the '980 record lists seven, adding Alberto Macciocchi. A continuation cannot ordinarily add an inventor absent a correction or a different inventive contribution — flag as an unresolved naming discrepancy, not a conclusion.
• A non‑inventor appears as an assignor. The 2018‑11‑14 Helsinn‑side assignment names "PANUCCIO, CARMINE" among the assignors, but Panuccio is not a named inventor on the '980 patent. This suggests the recorded instrument bundled inventors/contributors across the palonosetron family rather than the '980 alone.
• No departure pattern detectable. The 2018‑11‑14 confirmatory assignments show the Roche inventors (Malefyt, Miksztal, Lee) still assigning into Roche Palo Alto LLC ~15 years after the 2003 priority date, i.e., the opposite of a "all inventors bolted" tell. There is no recorded evidence of inventors leaving either assignee within 12 months of filing.

Original assignee

Co‑assignees of record on issue: Helsinn Healthcare SA (Lugano/Pazzallo, CH) and Roche Palo Alto LLC (Palo Alto, CA, US).

• Helsinn Healthcare SA — small, family‑owned Swiss pharmaceutical company (parent Helsinn Holding SA; ~200–250 employees around 1998 per Helsinn's own Supreme Court briefing). Primary line of business: branded supportive‑care pharmaceuticals. Product embodying the claims: Aloxi® (palonosetron HCl injection), NDA 021372, including the 0.25 mg/5 mL single‑use vial that is literally the subject of claim 1. FDA approved the injection 2003‑07‑25; the 0.25 mg/5 mL presentation is dated 2008‑02‑29. Aloxi was launched in the U.S. through a license/distribution arrangement with MGI Pharma (MGI later acquired by Eisai, 2008), with U.S. commercial rights ultimately held by Helsinn Therapeutics (U.S.), Inc. Manufacture has been attributed to Helsinn Birex Pharmaceuticals Ltd. (Ireland) (e.g., Vietnamese regulatory filing for Aloxi). Current status: operating, private, not in bankruptcy. Helsinn remains the Orange Book applicant/owner of Aloxi.
• Roche Palo Alto LLC — Roche's Palo Alto entity and successor to Syntex, which discovered palonosetron (U.S. 5,202,333, Syntex). Current status: Roche Holding AG is operating; Roche Palo Alto LLC exited this patent in the 2016‑05‑11 assignment to Helsinn (per Google Patents). Roche is the entity that initially "deemed the project too risky to pursue," per Helsinn's petition.

Assignment timeline

All dates below are the reassignment/recording dates reported by Google Patents legal events (execution dates are not exposed). Reel/frame and correspondent are unavailable to me — marked accordingly.

• 2016‑05‑11 (recorded) — Reel —/— (not retrievable)

  • Conveyance: Assignment of assignors' interest
  • Assignor: Roche Palo Alto LLC
  • Assignee: Helsinn Healthcare SA
  • Correspondent: not retrievable
  • Context: Internal consolidation — Roche exits co‑ownership; Helsinn becomes sole brand‑side owner.

• 2018‑11‑14 (recorded) — Reel —/— (not retrievable)

  • Conveyance: Assignment of assignors' interest
  • Assignor: Macciocchi, Alberto; Bonadeo, Daniele; Calderari, Giorgio; Cannella, Roberta; Panuccio, Carmine
  • Assignee: Helsinn Healthcare SA
  • Correspondent: not retrievable
  • Context: Late/confirmatory inventor‑to‑assignee perfecting assignment (15 yrs after priority); Panuccio is not a '980 inventor → likely bundled family instrument.

• 2018‑11‑14 (recorded) — Reel —/— (not retrievable)

  • Conveyance: Assignment of assignors' interest
  • Assignor: Malefyt, Thomas; Miksztal, Andrew; Lee, Kathleen M.
  • Assignee: Roche Palo Alto LLC
  • Correspondent: not retrievable
  • Context: Confirmatory inventor‑to‑assignee perfecting assignment on the Roche side.

• 2018‑11‑14 (recorded) — Reel —/— (not retrievable)

  • Conveyance: Patent Co‑Ownership Agreement
  • Assignor: Helsinn Healthcare SA
  • Assignee: Helsinn Advanced Synthesis SA; Helsinn Therapeutics (U.S.), Inc.; Helsinn Birex Pharmaceuticals Ltd.
  • Correspondent: not retrievable
  • Context: Internal group restructuring — title spread to four Helsinn operating entities (this matches the four plaintiffs jointly suing in Helsinn v. Baxter, D. Del. 1:18‑cv‑01674).

• 2018‑11‑21 (recorded) — Reel —/— (not retrievable)

  • Conveyance: Corrective Assignment (correcting spelling of "Helsinn Birex Pharmaceuticals Ltd." and assignee addresses)
  • Assignor: Helsinn Healthcare SA
  • Assignee: Helsinn Birex Pharmaceuticals, Ltd.; Helsinn Therapeutics (U.S.), Inc.; Helsinn Advanced Synthesis SA
  • Correspondent: not retrievable
  • Context: Record correction only — fixes the "HELSINN BIREX PHARMACEUTIALS LTD." typo in the co‑ownership recording.

• 2022‑12‑30 (recorded) — Reel —/— (not retrievable)

  • Conveyance: Security Interest (security agreement / collateral)
  • Assignor: Helsinn Birex Pharmaceuticals Limited; Helsinn Healthcare SA; Helsinn Therapeutics (U.S.), Inc.
  • Assignee (secured party): Hamilton SA LLC
  • Correspondent: not retrievable
  • Context: Securitization/financing — Helsinn pledged the portfolio to a secured party/lender. Not an ownership transfer.

• 2023‑09‑20 (recorded) — Reel —/— (not retrievable)

  • Conveyance: Release by Secured Party
  • Assignor: Hamilton SA LLC
  • Assignee: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
  • Correspondent: not retrievable
  • Context: Security interest discharged/terminated — the 2022 lien was released in full (no foreclosure, no sale).

Records exist, but with gaps: There are seven recorded post‑issuance events (so this is not a "no records" patent). However, the reel/frame and correspondent fields could not be captured from any source I could reach; I am not filling them in.

Timeline diagram

timeline
    title Ownership of US 9066980
    2003 : Priority application filed
    2013 : Continuation application filed
    2015 : Patent issued to Helsinn and Roche
    2016 : Roche assigns its stake to Helsinn
    2018 : Helsinn co-ownership agreement
         : Confirmatory inventor assignments
         : Corrective assignment recorded
    2022 : Security interest to Hamilton SA LLC
    2023 : Security interest released
    2024 : Patent expired

NPE / troll-pattern signals

1. Shell‑entity transfer — NOT PRESENT. Every owner in the chain is a real Helsinn Group operating entity: Helsinn Healthcare SA (parent brand holder), Helsinn Advanced Synthesis SA (Helsinn's API/active‑ingredient synthesis arm), Helsinn Birex Pharmaceuticals Ltd. (Irish manufacturer of Aloxi), and Helsinn Therapeutics (U.S.), Inc. (U.S. commercial arm; Rule 7.1 disclosure identifies parents Elus Holdings Corp. / Helsinn Holding S.A. / Elathon / Esker / Elesk Ireland). None is a licensing‑only "IP/Holdings/Ventures" shell. The sole non‑Helsinn entity, Hamilton SA LLC (2022‑12‑30 security interest), is a secured party, not an owner, and released its interest on 2023‑09‑20.
2. Known asserter in the chain — NOT PRESENT. No assignee matches Acacia, Marathon, Intellectual Ventures, IPNav, Wi‑LAN, Conversant/Mosaid, Vringo, Pendrell, Innovatio, MPHJ, Round Rock, or any Unified/RPX high‑frequency plaintiff. Stanford's NPE Litigation Database classifies the asserter in the '980 cases as "Product company" (e.g., Helsinn Healthcare S.A. et al v. Actavis LLC, 2:16‑cv‑01683 D.N.J.). URL: https://npe.law.stanford.edu/patent/9066980.
3. Repeat correspondent across the chain — UNVERIFIABLE. I could not obtain the assignment‑record correspondents. Non‑assignment context: Troutman Sanders LLP was identified by a generic challenger as the patent‑owner representative in USPTO PAIR for this family (FDA Docket, ANDA‑related filing), and Finnegan Henderson (Joseph M. O'Malley Jr., Eric Dittmann, Young Park, Isaac Ashkenazi, Dana Weir) served as litigation counsel in Helsinn v. Dr. Reddy's. Neither is a confirmed assignment correspondent and both are ordinary brand‑pharma counsel — no recurrence finding made.
4. Cascading transfers — NOT PRESENT. The 2018 cluster (three records on 2018‑11‑14 + one on 2018‑11‑21) is one corporate group engaging in an internal co‑ownership restructuring and a typo correction, not consecutive transfers through unrelated LLCs. No chained‑LLC conveyor, no shared registered‑agent addresses.
5. Pre‑litigation transfer — NOT PRESENT. Title has stayed within Helsinn/Roche since issue. The Roche→Helsinn assignment (2016‑05‑11) is an internal co‑owner buy‑out, not a suit‑enabling transfer to a new owner within 6 months of a first suit. Enforcement was brought by the patent owners themselves (Helsinn + Roche, later the four Helsinn entities).
6. Bankruptcy fire‑sale — NOT PRESENT. No Chapter 7/11. The 2022‑12‑30 security interest → 2023‑09‑20 release pattern shows a financing that was repaid/released, i.e., the opposite of a distressed liquidation.
7. Privateering — NOT PRESENT. The brand manufacturer sues ANDA filers directly to defend Aloxi; there is no transfer to an NPE asserting on Helsinn's behalf.
8. Defensive aggregator — NOT PRESENT. The chain terminates at Helsinn operating entities, not RPX, AST, LOT, Unified Patents, or OIN. (Note: RPX and Unified do maintain challenge/defensive coverage of the palonosetron family, but the title never moved to them.)

Verdict

Operating-company assertion.

Justification: The patent has been continuously owned by brand pharmaceutical companies — co‑assignees Helsinn Healthcare SA and Roche Palo Alto LLC — with Roche Palo Alto LLC assigning its stake to Helsinn on 2016‑05‑11 and title consolidated across four Helsinn Group operating entities via the 2018‑11‑14 Patent Co‑Ownership Agreement (corrected 2018‑11‑21). The only external party, Hamilton SA LLC, was a secured lender (security interest recorded 2022‑12‑30) whose interest was released 2023‑09‑20 — not an owner/asserter. The owners ship the patented product (Aloxi NDA 021372, 0.25 mg/5 mL vial) and asserted the '980 patent against generic competitors (Helsinn v. Actavis, 2:16‑cv‑01683 D.N.J.; Helsinn v. Fresenius Kabi, 1:15‑cv‑00918 D.Del.), and Stanford's NPE database labels the asserter a product company. No shell‑entity, known‑asserter, cascading‑transfer, fire‑sale, privateering, or defensive‑aggregator signal is present.

Verification link: https://assignmentcenter.uspto.gov/ (search patent number 9066980) — use this to fill the reel/frame and correspondent blanks above.

Cross‑checks against the previously generated sections (contradictions/additions flagged)

• Consistent: original assignees (Helsinn Healthcare SA + Roche Palo Alto LLC), current owners (the four Helsinn entities), and January 30, 2024 base expiration are all corroborated (Orange Book lists the '980 patent as expiring 2024‑01‑30, extended to 2024‑07‑30 with pediatric exclusivity).
• Additions the prior summary omitted: (i) the 2016‑05‑11 Roche→Helsinn exit assignment, (ii) the 2018 co‑ownership restructuring + corrective assignment, and (iii) the 2022/2023 Hamilton SA LLC security interest and release. The prior litigation list also did not include Actavis (2:16‑cv‑01683), Baxter (1:18‑cv‑01674), or Gavis (3:15‑cv‑01228).
• New source inconsistency to flag: FDA ANDA 201533 letter states litigation over the '094 and '980 patents was filed as Civil Action No. 14‑4274 — a 2014 filing — yet the '980 patent's issue date is June 2015. I am reporting both literally; the discrepancy is unresolved without the docket.
• Carried‑forward uncertainty: the issue date (June 20 vs. June 30, 2015) remains unresolved, and I again found no 2026 CAFC docket involving the '980 patent (report as "none found," not "none exists").

I'll research the prior art cited against US 9,066,980. Let me run several targeted searches.

Let me gather targeted details on the key cited references and the prosecution history.

Prior Art Analysis — US 9,066,980 B2 ("Liquid pharmaceutical formulations of palonosetron")

Scope, methodology, and caveats (read first)

⚠️ Verification limits. I was asked to search the USPTO database for the literal number 9066980. My searches returned the Google Patents full text and USPTO/PTAB litigation-derived copies of the '980 family (which I treat as authoritative per instructions), but my tool budget was exhausted before I could pull a clean, docket-level IDS/Form-892 (PTO/SB/08) "References Cited" sheet from USPTO PatentCenter for application 13/902,299 specifically. Therefore the citation list below is reconstructed from (a) the "Citations"/"Patent Citations" field of the '980 Google Patents record and (b) the identical front-page reference lists confirmed on the sibling family patents ('724, '725, '424, '219, '942). I flag where I am inferring rather than quoting.

⚠️ Style/ID discipline. All patent numbers, dates, and identifiers are reproduced literally as displayed on the '980 record and its family members; I have not normalized or auto-corrected any of them. Where two sources disagree (e.g., issue date), I report both.

⚠️ Contradiction flag vs. earlier sections. The earlier "Patent summary" section noted an issue-date discrepancy (Google Patents 2015-06-30 vs. a D.N.J. opinion's "June 20, 2015"). Nothing in the prior-art analysis below resolves or depends on that discrepancy; I leave it standing.

A threshold framing point that matters for § 102: US 9,066,980 claims priority to January 30, 2003 (Prov. 60/444,351), but was filed May 24, 2013 — i.e., after the AIA's March 16, 2013 change. Which § 102 regime governs (pre-AIA § 102(b)/(e) vs. AIA § 102(a)(1)/(a)(2)) turns on whether every claim retains a pre-March-16-2013 effective filing date — a question the Federal Circuit litigated to the Supreme Court for the sibling '219 patent in Helsinn v. Teva. I flag this because the "which § 102" answer changes the reference date and the on-sale analysis for several references below. I do not resolve it here.

1. The single most relevant reference: US 5,202,333 (Berger, Syntex)

Bottom line on Berger: It is the closest and most material prior art and the foundation of the art's disclosure of palonosetron, but it does not itself anticipate claims 1–16 as issued. Its § 102 exposure is limited to hypothetical broader claims (e.g., a bare "palonosetron or salt + carrier" genus, or the 0.000001%–10% w/v concentration genus recited in col. 12), which the issued '980 claims deliberately do not read on.

2. Patent citations that could bear on § 102 for the issued claims

These are the few examiner-cited references whose disclosure touches an element of the '980 claims. For each I give citation, dates, description, and the claim(s) it potentially reaches — with the explicit caveat that no single reference discloses every element of claims 1, 12, or 16, so none is a clean § 102 anticipation as issued.

2.1 — WO 2004/045615 A1 (Helsinn Healthcare SA)

• Filed / published: Nov. 15, 2002 / June 3, 2004 — "Palonosetron for the treatment of chemotherapy-induced emesis."
• Disclosure: Methods of treating acute and delayed CINV with palonosetron; expressly identifies the 0.25 mg/day dose and IV administration, and notes a ~40-hour half-life and dose plateau.
• Claims potentially anticipated: Claim 12 (method of reducing likelihood of CINV by IV administration before chemotherapy), and arguably the acute/delayed-typing of claims 14–15. Because its international filing date (2002-11-15) precedes the '980 priority date (2003-01-30), it is a candidate pre-AIA § 102(e) reference against the method claims — but it does not disclose the formulation elements (0.25 mg in 5 mL, optional chelating agent, isotonic tonicifier, 24-month stability) that define claims 1–11 and 16.

2.2 — WO 2004/073714 A1 (Helsinn Healthcare S.A.)

• Filed / published: Feb. 18, 2003 / Sept. 2, 2004 — "Use of palonosetron [for] treating post-operative nausea and vomiting (PONV)."
• Disclosure: Palonosetron for PONV.
• Claims potentially anticipated: Relevant only as background; directed at PONV, not CINV, and its filing date (2003-02-18) post-dates the '980 priority date. On the '980's own priority it is not prior art at all for the claims as written.

2.3 — WO 2003/100091 A1 (Epidauros Biotechnologie AG)

• Filed / published: May 24, 2002 / Dec. 4, 2003 — "Means and methods for improved treatment using 'setrones'."
• Disclosure: Pharmacogenomic/genotypic stratification of setron (5-HT₃ antagonist) therapy.
• Claims potentially anticipated: None specifically. Filed before the priority date, it is a § 102(e) candidate, but it is directed to patient selection, not the '980 formulation or dosing method.

2.4 — US 2004/0147510 A1 (Dynogen Pharmaceuticals, Inc.)

• Filed / published: Jan. 13, 2003 / July 29, 2004 — "Method of treating nausea, vomiting, retching or any combination thereof."
• Disclosure: Treatment methods for nausea/emesis (not palonosetron-specific).
• Claims potentially anticipated: Potentially claim 12 only in the broadest sense of "method of treating nausea/vomiting"; filed 2003-01-13, i.e., 17 days before the '980 priority date, so it is a narrow § 102(e) candidate — but it does not disclose the palonosetron formulation of claims 1/16.

2.5 — US 6,694,852 B2 / US 7,109,339 B2 (Bristol-Myers Squibb)

• Filed / published: Dec. 20, 2000 / Mar. 2, 2004; and Dec. 19, 2002 / Sept. 19, 2006 — "Substituted pyridoindoles" / "Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists."
• Disclosure: 5-HT receptor ligands (agonists/antagonists) — chemistry, not palonosetron formulations.
• Claims potentially anticipated: None. Different compounds; no formulation disclosure.

2.6 — US 6,284,770 B1 / US 5,360,800 A (alosetron) — background

• Dates: 2000-09-04 / 1993-08-31 — alosetron and its uses (GlaxoSmithKline's Lotronex®).
• Disclosure: A different 5-HT₃ antagonist.
• Claims potentially anticipated: None. Cited for the general state of the 5-HT₃-antagonist art.

3. Patent citations directed to other 5-HT₃ antagonists (ondansetron / granisetron / dolasetron / tropisetron) — no § 102 anticipation of the palonosetron claims

These references are cited on the '980 face but each discloses a structurally distinct active ingredient. Because anticipation requires that a single reference disclose all elements arranged as in the claim (including, here, palonosetron HCl), none anticipates claims 1–16. They are relevant only as evidence of the general formulation toolkit (buffers, tonicifiers, chelators) and as § 103 support.

4. Formulation-toolkit / excipient references (relevant to dependent claims 2–11, but non-anticipatory)

These were cited for the general parenteral-formulation state of the art. They could support § 103 obviousness of dependent-claim excipients, but each lacks palonosetron and/or the specific claimed values, so none anticipates.

Note: US 5,272,137 (McNeil-PFC) and EP 0 512 400 (Searle) are the type of reference cited to show that suspending/buffering/chelating excipients were routine — useful for § 103, not § 102.

5. Same-family / same-priority references on the '980 face — NOT prior art

The following appear in the '980 citation list but share the January 30, 2003 priority (or are the '980's own priority documents). Under § 102 they cannot be "prior art." I list them so they are not mistaken for anticipatory art:

• WO 2004/067005 A1 — filed 2003-01-30 / published 2004-08-12 (Helsinn) — this is the PCT parent of the '980 family, i.e., the priority document itself, not prior art.
• US 7,947,724 B2; US 7,947,725 B2; US 7,960,424 B2; US 8,518,981 B2; US 8,598,218 B2; US 8,598,219 B2 — sibling family patents, all priority 2003-01-30.
• US 2013/0261149 A1; US 2013/0261150 A1; US 2013/0289065 A1; US 2014/0039000 A1 — family publications, priority 2003-01-30.
• US 5,510,486 A; US 5,567,818 A (Syntex) — palonosetron synthesis filings (these are the "Family Cites Families" entries) — chemistry only.

6. Non-patent literature bearing on § 102 (flagged for completeness)

The '980 face lists 318 non-patent citations. The ones most relevant to § 102 anticipation for the method claims are:

• The Phase II Study 2330 Final Report (dated July 1995; signed Sept. 25, 1995) — reported that a single IV bolus of palonosetron 30 minutes prior to high-dose cisplatin suppressed emesis for 24 hours (0.25 mg dose discussed). This is a candidate § 102(b) printed-publication/sale reference against claim 12 depending on its public availability before Jan. 30, 2002/2003.
• Aapro et al.; Gralla et al.; Eisenberg et al. — Phase III CINV reports (2003–2006).
• The MGI Pharma License and Supply Agreements (April 6, 2001) and their Form 8-K disclosure — the on-sale-bar art at the heart of Helsinn v. Teva, relevant to § 102(b) for the 0.25 mg dose claims.

7. Direct answers to the four requested data points, condensed

8. Bottom-line conclusion

1. No cited reference squarely anticipates claims 1, 12, or 16 of US 9,066,980. The patent's validity fights were fought on § 103 obviousness (Berger as primary reference) and on the § 102(b) on-sale bar against the sibling patents — not on § 102 anticipation of the '980 claims.
2. US 5,202,333 (Berger/Syntex) is the most relevant prior art: it discloses palonosetron and an IV formulation, but at a pH (3.7) and concentration (10–100 mg/mL) far outside the claimed ranges, and without the isotonic/chelator/24-month-stability limitations.
3. WO 2004/045615 is the only examiner-cited reference with realistic § 102(e) exposure, and only to the method claims (12–15), because it predates the priority date and discloses the 0.25 mg CINV dose — but not the claimed formulation.
4. Every "same-family" reference on the face of the '980 (WO 2004/067005, the '724/'725/'424/'981/'218/'219 patents, and the 2013–2014 publications) is disqualified as prior art by shared priority.

Confidence: High that Berger is the primary reference and that no cited reference anticipates the issued claims as written; medium on the precise § 102(e) status of WO 2004/045615 and US 2004/0147510 (turns on the unresolved pre-AIA/AIA effective-filing-date question flagged in § 1); low on the completeness of my citation list, because I could not retrieve the actual Form-892/IDS for application 13/902,299 from USPTO PatentCenter before exhausting my tool budget. For any legal purpose, verify the citation list against the '980 file wrapper in PatentCenter and re-run a literal PACER/PTAB check.

I'll ground this § 103 analysis in the prior art actually cited on the patent page. Let me verify the key references before combining them.

Let me verify a few key secondary references and any PTAB/IPR record on this patent.

Obviousness Analysis — U.S. Patent 9,066,980 under 35 U.S.C. § 103

Built on the prior "Patent summary" and "Litigation summary" sections; those sections established the claim text, the continuity chain, and the fact that the D.N.J. (Feb. 14, 2017) sustained the asserted claims against § 112 attacks and that the Federal Circuit's on‑sale‑bar decision (Teva) did not reach the '980 claims. This section does not repeat those findings except where they bear on the § 103 question.

I. Threshold: which § 103 framework applies, and to what date

The '980 patent issued after September 16, 2012, so it is governed by the AIA. The D.N.J. confirmed this expressly: "The '094 and '980 patents were filed after September 16, 2012, and are governed by the Leahy‑Smith America Invents Act." See Case 3:12‑cv‑02867‑MLC‑DEA, Doc. 232 at 6 n.33 (D.N.J. Feb. 14, 2017), https://cases.justia.com/federal/district-courts/new-jersey/njdce/3:2012cv02867/[274275/232](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=274275-0232)/0.pdf.

The claims trace back to U.S. Provisional 60/444,351 (Jan. 30, 2003) and PCT/EP2004/000888 (WO 2004/067005, filed Jan. 30, 2004). On the patent's face the earliest priority date is January 30, 2003. For real‑party prior‑art dating, the record reflects that the operative publication cut‑off used in the parallel litigation was January 30, 2002 for pre‑AIA § 102(b) purposes (see BIPC opinion, https://www.bipc.com/assets/PDFs/Insights/Opinion-Intellectual_Property-Helsinn_Healthcare_v_Teva_Pharmaceuticals_USA-20160303.pdf: "the published prior art in this case is defined under 35 U.S.C. § 102(b) … January 30, 2002").

⚠️ Flag for the analyst: because the patent is post‑AIA, art published between Jan. 30, 2002 and Jan. 30, 2003 (e.g., Akers 2002, J. Pharm. Sci. 91(11):2283‑2300, Nov. 2002) is reachable as § 102(a)(1) art even though it fails the § 102(b) grace‑period test. I do not have the litigation record confirming how the parties treated Akers, so I mark that reference as AIA‑only art.

POSA definition. A person of ordinary skill in the art would be a pharmaceutical formulation scientist (Ph.D. or M.S. with several years in parenteral product development) familiar with 5‑HT₃ antagonist antiemetics and with standard parenteral formulation practice (buffers, tonicifiers, chelators, terminal sterilization, ICH stability testing). The '980 specification itself is written to that audience — its examples are routine experimental‑design studies.

II. The claims to be analyzed

Critical structural observation: claim 1 uses "optionally a chelating agent." A chelator is therefore not required for infringement of claim 1 or claim 16. This materially weakens the patentee's ability to rely on the "unexpected EDTA stability" story to defend the independent claims — that evidence is cabined to dependent claims 6–9.

III. The prior art of record, grouped by function

Page's "Citations (28)" and "Non‑Patent Citations (318)" supply the following building blocks:

A. The palonosetron "compound + first formulation" reference

• US 5,202,333 (Syntex/"Berger") — tricyclic 5‑HT₃ antagonists. The '980 specification itself quotes Berger's Example 13 IV formulation verbatim:

  Ingredient	Amount
  Palonosetron HCl	10–100 mg
  Dextrose monohydrate	q.s. to make isotonic
  Citric acid monohydrate	1.05 mg
  Sodium hydroxide	0.18 mg
  WFJ	to 1.0 mL

  The patent states this formulation "has a pH of 3.7 and a shelf stability of less than the 1‑2 year time period required by health authorities." (See '980 description; AU2004208505B2 mirror, https://patentimages.storage.googleapis.com/07/25/7a/6ec593aa71e878/AU2004208505B2.pdf.) Berger also discloses the full dosage genus ("700 ng/day to 7.0 mg/day") and all routes, including IV.

• US 5,510,486 (Syntex) — process for making the benz[de]isoquinolinone (palonosetron) compounds.

• Eglen et al. 1995, Br. J. Pharmacol. 114:860‑866 — pharmacological characterization of RS 25259‑197 (palonosetron), cited in the '980 list.

• Gaster & King 1997, Med. Res. Rev. 17(2):163‑214 — 5‑HT₃/5‑HT₄ antagonist review.

B. The palonosetron indication references (for the method claims)

• WO 2004/045615 (Helsinn) — "Palonosetron for the treatment of chemotherapy‑induced emesis" (priority Nov. 15, 2002; pub. June 3, 2004). Cited in the '980 list.
• WO 2004/073714 (Helsinn) — "Use of palonosetron [for] treating post‑operative nausea and vomiting" (priority Feb. 18, 2003).
• US 2004/0147510 (Dynogen) — "Method of treating nausea, vomiting, retching or any combination thereof" (cited by the examiner).

C. 5‑HT₃‑antagonist formulation art (class‑level teaching)

• US 6,294,548 (Hoffmann‑La Roche) and US 2001/0020029 (SmithKline Beecham) — multidose‑vial formulations for granisetron HCl (an azabicyclo 5‑HT₃ antagonist); direct class analogue for vialling a 5‑HT₃ antagonist injectable.
• US 5,955,488 / US 6,063,802 (Glaxo Wellcome) — ondansetron freeze‑dried dosage forms.
• US 5,272,137 (McNeil‑PFC) — aqueous pharmaceutical suspension.
• US 6,287,592 (Boots) — aqueous drink composition (liquid oral formulation know‑how).

D. Stabilized‑liquid / chelator art (for claims 6–9)

• US 5,866,154 (DuPont Merck) — "Stabilized naloxone formulations."
• US 6,132,758 (Schering) — "Stabilized antihistamine syrup."
• Won et al. 1995, Int'l J. Pharmaceutics 121:95‑105 — "Photolytic and oxidative degradation of an antiemetic agent, RG 12915." This is the linchpin secondary reference: it teaches that a structurally related 5‑HT₃‑type antiemetic degrades by oxidative pathways — the classic reason to add a chelator/antioxidant.
• Akers, "Excipient‑Drug Interactions in Parenteral Formulations," J. Pharm. Sci. 91(11):2283‑2300 (Nov. 2002).

E. Tonicifier / mannitol art (for claims 3–5)

• US 2,836,541 (Sterling Drug) — "Mannitol stabilized morphine‑papaverine composition."
• Handbook of Pharmaceutical Excipients (3d ed. 2000; 6th ed. 2009) — lists mannitol as a tonicity agent and EDTA and citric acid as buffering/chelating excipients.
• Modern Pharmaceutics (2d ed. 1990), Lachman, Theory & Practice of Industrial Pharmacy (3d ed. 1986), DeLuca et al., Formulation of Small Volume Parenterals (1992) — standard parenteral tonicity/buffer practice.

F. Manufacturing / terminal‑sterilization and unit‑dose art (for the 5 mL single‑use, 24‑month‑stable limitation)

• US 5,439,643 (Liebert) — "Method and apparatus for terminal sterilization."
• US 5,597,530 (Abbott) — "Process for prefilling and terminally sterilizing syringes."
• US 6,294,548 / US 2001/0020029 — vial presentations.

G. Stability/analytical background

• Connors, Chemical Stability of Pharmaceuticals (2d ed. 1986); Pikal, "Freeze Drying" (2007); Mayron 1996, Am. J. Health‑Syst. Pharm. 53:294‑304 (granisetron stability in IV solutions/oral liquids).

H. Clinical dosing literature establishing the 0.25 mg IV dose

• Macciocchi et al., ASCO 2002, Abstract 1480 — Phase II dose‑ranging.
• Grunberg et al., MASCC June 2002, Abstract P‑113 — the PALO‑99‑04 data; the D.N.J. found this was publicly presented June 23–26, 2002 in Boston.
• Eisenberg et al. 2003/2004, Cancer 98(11):2473‑2482 and Ann. Oncol. 15:330‑337.
• FDA Statistical Review for NDA 21‑372 (2003) — records that the applicant sought approval of "a single, intravenous injection of palonosetron 0.25 mg, given 30 minutes prior to" chemotherapy (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21‑372_Alox_Statr.pdf).

IV. Ground 1 — The primary formulation combination

References: US 5,202,333 (Berger) + Eglen 1995 (palonosetron characterization) + the clinical dosing literature (Macciocchi 2002 / Grunberg 2002 / Eisenberg) + Handbook of Pharmaceutical Excipients / DeLuca (routine parenteral formulation).

Element‑by‑element mapping to claim 1:

Motivation to combine. Berger itself supplies the motivation: it discloses an IV palonosetron formulation that is unstable (pH 3.7; shelf life < 1–2 years). An express statement of a problem in the primary reference is the paradigm case for a motivation to improve. The '980 specification concedes the same problem ("an object of the present invention [is] to provide a formulation … with increased pharmaceutical stability"). A POSA would therefore look to (i) the clinically established 0.25 mg dose to define the commercial unit dose, and (ii) standard parenteral formulation textbooks to select a buffer, pH, tonicifier, and container.

This is the combination DRL actually pressed at the PTAB. DRL's petition argued "It would be obvious to modify the Berger and Eglen references" and that the ingredient/range choices "would have been done as a matter of course" (see DRL IPR petition excerpts, https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1458462](/patent/1458462)/download-documents?artifactId=2CK0bEKmr_KAlOwh_27WDRKr6EB0amlcSagvEnyhudGT5vFZsZpykhs). Notably, DRL admitted Berger and Eglen did not teach the specific concentration, pH, mannitol‑for‑dextrose substitution, or the 20 mM buffer — which shows where the obviousness case is strongest (the genus) and weakest (the exact species).

KSR overlay. Under KSR Int'l v. Teleflex, 550 U.S. 398 (2007), a formulation that is "a combination of familiar elements according to known methods" yielding "predictable results" is obvious; and where there are "a finite number of identified, predictable solutions," a POSA has good reason to pursue them. pH, buffer identity/strength, tonicifier, chelator, and fill volume are exactly that class of variables.

V. Ground 2 — Adding the chelator references (claims 6–9)

References: Ground 1 + Won 1995 (oxidative degradation of an antiemetic 5‑HT₃ agent) + Akers 2002 (excipient–drug interactions in parenterals) + US 5,866,154 (stabilized naloxone) + US 6,132,758 (stabilized antihistamine syrup).

Why a POSA would add EDTA. Won 1995 is in the '980's own prior‑art list and teaches that a structurally analogous antiemetic degrades by a photolytic/oxidative route — the textbook trigger for a chelating agent (e.g., disodium edetate) in a parenteral. Akers 2002 teaches that trace‑metal‑catalyzed oxidation in parenterals is routinely addressed with a chelator. US 5,866,154 and US 6,132,758 supply concrete, analogous "stabilize a liquid drug with a chelating agent" teachings. The dependent ranges (0.005–1.0 mg/mL; optimally 0.5 mg/mL) sit squarely within the conventional 0.01–0.1% w/v EDTA parenteral range.

Counter‑evidence the examiner/patentee would cite: the '980 specification asserts (in the Bonadeo material) that EDTA's benefit was "somewhat surprising, given our earliest work with the molecule, in which palonosetron demonstrated comparable stability at 5 °C as it did at 60–100 °C" — i.e., the degradation did not look like classic auto‑oxidation. This is a genuine "unexpected results" argument, but it is directed at dependent claims 6–9, not independent claims 1/16.

VI. Ground 3 — Mannitol as the tonicifier (claims 3–5)

References: Ground 1 + US 2,836,541 (mannitol‑stabilized composition) + Handbook of Pharmaceutical Excipients (mannitol as tonicity agent) + US 5,272,137 / US 6,132,758.

Mannitol is one of the two most common parenteral tonicifiers (with NaCl/dextrose), and its 41.5 mg/mL value is simply the standard isotonic concentration (~0.9% NaCl equivalent; 5.0% dextrose equivalent). The patent itself concedes this is arithmetic: "The optimum level of mannitol required for an isotonic solution was found to be 4.15%." Under KSR, selecting a known tonicifier from a small, known set to achieve isotonicity is an obvious design choice. The patentee's contrary evidence — that mannitol gave superior stability relative to sodium chloride (Example 3) — is a classic "unexpected results" rebuttal, but it is legally vulnerable because (a) it is not commensurate with the full scope of the dependent claim, and (b) the specification describes it as one of many routine screening experiments.

VII. Ground 4 — The method‑of‑use claims (12–15)

References: WO 2004/045615 (palonosetron for CINV) + US 2004/0147510 (Dynogen; treating nausea/vomiting) + the clinical literature (Macciocchi 2002; Grunberg 2002; Eisenberg 2003/2004; Aapro 2003) + Ground 1 formulation.

• "reduce the likelihood of CINV … administered before the start of chemotherapy" — taught by WO 2004/045615 and by the FDA‑reviewed Phase III protocols, in which palonosetron was given 30 minutes before chemotherapy.
• "over a period of 10 to 60 seconds" (claim 13) — the FDA Statistical Review records the clinical dose as "0.25 mg IV administered over 30 seconds"; slow IV push over ~30 s is standard nursing practice. This is a KSR "obvious to try"/routine‑optimization limitation par excellence.
• acute vs. delayed (claims 14–15) — both the acute (0–24 h) and delayed (2–5 day) endpoints were the express study objectives publicized in the 2002 abstracts.

Caveat / contradiction flag: the Method claim's obviousness weight depends on whether WO 2004/045615 counts as prior art. It has a Nov. 15, 2002 priority date (per the '980 citation table) but published June 3, 2004 — after the Jan. 30, 2003 effective filing date. It can only be § 102(a)(2) art if it qualifies as a U.S.‑designating published application effectively filed before Jan. 30, 2003, and it is not excepted by common ownership/inventorship (§ 102(b)(2)(C)). Because it is a Helsinn document in the same corporate family, I cannot treat it as unqualified prior art; the method claims are more safely attacked via the public clinical literature (Grunberg June 2002 abstract; FDA NDA 21‑372 record), which is third‑party‑dated.

VIII. Ground 5 — Unit‑dose packaging and 24‑month shelf life

References: Ground 1 + US 5,439,643 (terminal sterilization) + US 5,597,530 (prefilling/terminally sterilizing syringes) + US 6,294,548 / US 2001/0020029 (vials).

Claim 1's "single‑use, unit‑dose … 5 mL" and "stable at 24 months when stored at room temperature" are functional/format limitations. The '980 specification frames 24‑month room‑temperature stability as an objective to be met via formulation, not as an independently inventive act ("shelf stable for periods greater than 24 months at room temperature, and thus can be stored without refrigeration, and manufactured using non‑aseptic, terminal sterilization processes"). US 5,439,643 and US 5,597,530 teach the terminal‑sterilization manufacturing step that the specification claims as an advantage. A POSA optimizing Berger's formulation by pH/buffer/tonicifier selection would arrive at a room‑temperature‑stable product as a matter of routine stability testing; the "24‑month" figure is a result‑effective variable obtainable by routine ICH protocols.

IX. Motivation to combine and reasonable expectation of success (the KSR backbone)

1. Same field, same problem. All primary references concern injectable antiemetics / 5‑HT₃ antagonists. No field‑of‑use barrier.
2. Express problem in the primary reference. Berger discloses instability (pH 3.7) — an express "improvement needed" signal.
3. Predictable art. Parenteral solution formulation (buffering to a target pH, isotonicity, chelation) was, by 2002, a mature, predictable art (DeLuca 1992; Lachman 1986; Akers 2002). KSR: "predictable variations of prior art" + "design incentives" = obvious.
4. Finite set of options. Tonicifier (mannitol/NaCl/dextrose), buffer (citrate/acetate/phosphate), chelator (EDTA) — a small, closed menu; DRL's own Aloxi‑bioequivalent 505(b)(2) used acetate instead of citrate and omitted EDTA (see NDA 203050 review, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203050Orig1s000OtherR.pdf), which underscores how routine these excipients are.
5. Reasonable expectation of success. A POSA would expect pH‑buffering and chelation to improve stability of an amine drug; no unpredictable mechanism needed.

X. Rebuttal — why the § 103 case is nonetheless contestable

This is where the patentee's record is strong, and any honest analysis must weigh it:

1. Presumption of validity + clear‑and‑convincing standard. The '980 claims are post‑AIA but were never invalidated; the D.N.J. rejected DRL's § 112 challenges (enablement/written description) outright (Doc. 232).
2. Teaching away (Tang 1998). The patentee argued at the PTAB that Tang 1998 taught that the 0.05 mg/mL / 0.25 mg dose was ineffective — i.e., the prior art pointed away from the very dose limitation central to claim 1 (petition response, https://ptacts.uspto.gov/ptacts/public-informations/petitions/1458462/download-documents?artifactId=2CK0bEKmr_KAlOwh_27WDRKr6EB0amlcSagvEnyhudGT5vFZsZpykhs).
3. Enormous genus + no direction. Berger's dose/concentration ranges were called "huge" (700 ng – 7.0 mg/day), and Example 13's 10–100 mg/mL is 40–400× the claimed 0.05 mg/mL. Patentee invokes the Cyclobenzaprine "throwing metaphorical darts" and Insite hindsight line of cases.
4. Unexpected results (Fed. Cir. WBIP framework). The record contains sworn declarations (Bonadeo; Calderari/Bonadeo/Cannella/Braglia) that (a) lower palonosetron concentration gives greater stability (counter to expectation), (b) mannitol outperformed NaCl, and (c) EDTA's benefit was surprising given the molecule's thermal stability profile. These are classic secondary‑consideration evidence — but they primarily support dependent claims, because claim 1 requires neither mannitol specifically nor any chelator.
5. Hindsight posture. The PTAB has repeatedly rejected § 103 attacks on formulation claims built on "would have been done as a matter of course" reasoning that lacks an articulated reason for the specific combination (Purdue v. Depomed, IPR2015‑00378; Endo v. Depomed, IPR2014‑00652), and the DRL petition was criticized on precisely this basis.

Net: the deepest vulnerability is the broad independent claims 1/16, because "optionally a chelating agent" + "a tonicifying agent" + functional stability language + a dose/species selection arguably reachable from Berger + routine formulation optimization is the least‑supported scope. The narrow dependent claims (2–11) — especially the mannitol‑41.5 / EDTA‑0.5 / citrate‑20 mM / pH‑5.0 species — are defended by concrete unexpected‑results evidence and are much harder to invalidate.

XI. Bottom line

• Strongest combination (claims 1 and 16): US 5,202,333 (Berger) + Eglen 1995 + the 2002 clinical dose literature (Macciocchi; Grunberg) + standard parenteral formulation texts (DeLuca; Lachman; Handbook of Pharmaceutical Excipients), with US 6,294,548 as class‑level vialling art. Motivation: Berger's own admitted instability; predictability of parenteral formulation; finite, known excipient options (KSR).
• Add for claims 6–9: Won 1995 + Akers 2002 + US 5,866,154 (chelator rationale).
• Add for claims 3–5: US 2,836,541 + Handbook of Pharmaceutical Excipients (mannitol tonicifier).
• For claims 12–15: WO 2004/045615 + US 2004/0147510 + clinical literature (mind the § 102(a)(2)/common‑ownership caveat on WO 2004/045615).
• For claims 12 and the 24‑month limitation: US 5,439,643 + US 5,597,530 (terminal sterilization / prefilled unit dose).
• Where it likely fails: the mannitol‑/EDTA‑specific dependent claims and any claim captured by the patentee's unexpected‑stability and teaching‑away evidence; and the independent claims face the Insite/hindsight and "no articulated reason for the specific species" defense that carried weight in the related PTAB proceedings.

Confidence / uncertainty

• High confidence: the reference set and their content (drawn from the '980 page's own citation lists and corroborated by the AU2004208505B2/Ex. 13 text, the FDA NDA 21‑372 review, and the PTAB petition excerpts).
• Explicit uncertainty: (1) I could not confirm a full, final § 103 merits ruling on the '980 claims — the retrieved D.N.J. Feb. 14, 2017 opinion addresses § 112 (enablement/written description), and the obviousness fight is documented mainly through PTAB petition/response excerpts and DRL's invalidity contentions; (2) the prior‑art status of WO 2004/045615 for the '980 claims turns on AIA § 102(a)(2)/(b)(2)(C) common‑ownership facts I cannot verify; (3) Akers 2002 qualifies under AIA § 102(a)(1) but not pre‑AIA § 102(b), and I lack the record showing which the parties applied to the '980. Verify (1)–(3) against PACER/PTAB and the '980 file history before relying on any of them for a legal conclusion.